This study shows that it is possible to achieve a significant improvement in the functional status and QoL of cancer patients using epoetin β. Studies examining the cost-effectiveness of epoetin used in the cancer setting have produced mixed conclusions, but these findings are based on clinical trial results from the early-to-mid 1990s (Cremieux et al, 1999; Sheffield et al, 1997). Here, EPO is linked to cancer.